Attovia Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in November 2026, including the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference. The company will discuss its next-generation biotherapeutics for immune-mediated diseases, highlighting its lead programs such as ATTO-1310 and ATTO-2306. These events provide Attovia an opportunity to engage with investors and showcase progress in its clinical and IND-enabling studies. Webcasts and replays will be available for investors to follow the presentations.
Attovia Therapeutics is set to participate in several investor conferences in November 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 03:11 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 88 rose and 62 fell today. Notable movers include TWST (Twist Bioscience Corp) at USD 159.95 with a 1-day change of +10.12% and Pluang order activity of 0% Sell / 100% Buy, MRVI (Maravai LifeSciences Holdings Inc.) at USD 8.21 with a 1-day change of +8.38%, and DYN (Dyne Therapeutics Inc.) at USD 16.93 with a 1-day change of +7.70%.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
